Cross-sectional analysis of the Parkinson’s disease Non-motor International Longitudinal Study baseline non-motor characteristics, geographical distribution and impact on quality of life

Growing evidence suggests that non-motor symptoms (NMS) in Parkinson’s disease (PD) have differential progression patterns that have a different natural history from motor progression and may be geographically influenced. We conducted a cross-sectional analysis of 1607 PD patients of whom 1327 were...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Scientific reports Ročník 11; číslo 1; s. 9611 - 11
Hlavní autoři: van Wamelen, Daniel J., Sauerbier, Anna, Leta, Valentina, Rodriguez-Blazquez, Carmen, Falup-Pecurariu, Cristian, Rodriguez‐Violante, Mayela, Rizos, Alexandra, Tsuboi, Y., Metta, Vinod, Bhidayasiri, Roongroj, Bhattacharya, Kalyan, Borgohain, Rupam, Prashanth, L. K., Rosales, Raymond, Lewis, Simon, Fung, Victor, Behari, Madhuri, Goyal, Vinay, Kishore, Asha, Lloret, Santiago Perez, Martinez-Martin, Pablo, Chaudhuri, K. Ray
Médium: Journal Article
Jazyk:angličtina
Vydáno: London Nature Publishing Group UK 05.05.2021
Nature Publishing Group
Nature Portfolio
Témata:
631/378
631/378/1689
631/378/1689/1718
692/1807/1693
Cross-sectional studies
Emotional behavior
Geographical distribution
Humanities and Social Sciences
Longitudinal studies
Mood
Movement disorders
multidisciplinary
Neurodegenerative diseases
Parkinson's disease
Phenotypes
Quality of life
Science
Science (multidisciplinary)
Sleep
Asia
Europe
ISSN:2045-2322, 2045-2322
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Growing evidence suggests that non-motor symptoms (NMS) in Parkinson’s disease (PD) have differential progression patterns that have a different natural history from motor progression and may be geographically influenced. We conducted a cross-sectional analysis of 1607 PD patients of whom 1327 were from Europe, 208 from the Americas, and 72 from Asia. The primary objective was to assess baseline non-motor burden, defined by Non-Motor Symptoms Scale (NMSS) total scores. Other aims included identifying the factors predicting quality of life, differences in non-motor burden between drug-naïve and non-drug-naïve treated patients, and non-motor phenotypes across different geographical locations. Mean age was 65.9 ± 10.8 years, mean disease duration 6.3 ± 5.6 years, median Hoehn and Yahr stage was 2 (2–3), and 64.2% were male. In this cohort, mean NMSS scores were 46.7 ± 37.2. Differences in non-motor burden and patterns differed significantly between drug-naïve participants, those with a disease duration of less than five years, and those with a duration of five years or over (p ≤ 0.018). Significant differences were observed in geographical distribution (NMSS Europe: 46.4 ± 36.3; Americas: 55.3 ± 42.8; Asia: 26.6 ± 25.1; p < 0.001), with differences in sleep/fatigue, urinary, sexual, and miscellaneous domains (p ≤ 0.020). The best predictor of quality of life was the mood/apathy domain (β = 0.308, p < 0.001). This global study reveals that while non-motor symptoms are globally present with severe NMS burden impacting quality of life in PD, there appear to be differences depending on disease duration and geographical distribution.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-021-88651-4